Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of etanercept in steroid-unresponsive Stevens-Johnson syndrome/toxic epidermal necrolysis
jRCTs031210325Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Time to complete re-epithelialization. Started Oct 2021; status: completed.
02
Drugs
etanercept
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on jRCTs031210325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210325.